Home » Health » Clinical Trials of Convalescent Plasma Therapy in Indonesia are Phase 2-3, What Are the Targets? All pages

Clinical Trials of Convalescent Plasma Therapy in Indonesia are Phase 2-3, What Are the Targets? All pages

KOMPAS.com– Development therapy plasma convalescent at Indonesia has entered phase 2-3, namely assessing the efficacy or benefit (efficacy) of the administration convalescent plasma against Covid-19 patients.

This was conveyed by the Deputy Head of Translational Research at the Institute of Molecular Biology (LBM) Eijkman, Prof. Dr. David H Muljono SpPD FINSASIM FAASLD PhD.

David explained, phase 1 conventional plasma therapy, which is testing the safety of the therapy, has been completed. Although the protocol guidelines for administering convalescent plasma therapy to Covid-19 patients do not exist until now.

Convalescent plasma administration has been used since a century ago, including since the Spanish flu pandemic, Ebola pandemic, and bird flu pandemic.

Also read: US Permits Convalescent Plasma Therapy to Treat Covid-19 Patients, What Is It?

“And it is proven that the plasma is safe and good enough, but the results are not yet a pattern to make as general guidelines,” said David in Kick-off Meeting for Clinical Trials Plasma Convalescent as Therapy Additional Covid-19 via the BalitbangkesTV Youtube channel, Tuesday (8/9/2020).

Target the efficacy of phase 2-3 clinical trials

David said, from tests that have been carried out in China and America, this convalescent plasma therapy has been proven safe and is good enough to be given to Covid-19 patients.

In Indonesia itself, a phase 1 clinical trial for safety testing has also been initiated at the Gatot Subroto Army Hospital for several patients and has been completed, and is currently under reporting.

Also read: Convalescent Plasma for Covid-19 Treatment, Here Are the Conditions to Become a Donor

In addition, the Ministry of Research and Technology / National Agency for Research and Innovation in collaboration with 8-10 hospitals is also conducting phase 1 clinical trials of conventional plasma therapy.

“However, when viewed from the other side, namely the benefits, efficacy (efficacy), it raises questions,” said David.

This efficacy is closely related to how the patient can recover, what is the cure rate from convalescent plasma therapy, and which patient can recover.

In this clinical trial, it is hoped that convalescent plasma as a product needs to be investigated further to answer some basic questions as target giving therapy.

photo" data-photolink="http://www.kompas.com/sains/image/2020/09/08/193600323/uji-klinis-terapi-plasma-konvalesen-indonesia-sudah-fase-2-3-apa-targetnya?page=2" style="max-width: 100%;width:750px">BETWEEN PHOTOS / NOVA WAHYUDI TNI AD soldiers donated blood plasma at the Blood Transfusion Unit (UTD) Gatot Soebroto Central Army Hospital (RSPAD), Jakarta, Tuesday (18/8/2020). The collection of convalescent plasma of patients cured of COVID-19 using an apheresis device aims to help cure patients with confirmed COVID-19.-

Among them are, what is the most appropriate dose to be given, how to administer therapy, when (timing) is appropriate to administer, as well as a good schedule for the patient to be given therapy.

“This is the task and the result is awaited all over the world, including Indonesia,” he said.

Thus, the drafting team will compile a convalescent plasma therapy protocol by taking into account related reports from various countries in the world, with existing regulators, and considering clinical trial existing protocol and need to be studied.

“There are some (countries) have completed (convalescent plasma therapy protocols) with points timing to be important. Some have, but are given only to groups (Covid-19 patients) who are critical, “he said.

Also read: United States Permits Covid-19 Treatment With Convalescent Plasma, Here’s How It Works

Learning from the protocol and also the mechanism for administering this conventional plasma therapy, Indonesia must really consider the efficacy (efficacy) and safety (safety) above the speed of implementing this therapy.

The protocol is also expected to be able to answer all the basic questions regarding the effectiveness of the success of conventional plasma therapy for patients infected with Covid-19 in the moderate and severe categories.

Meanwhile, four hospitals that started the phase 2-3 clinical trial for simultaneous plasma therapy today are the Dr Ramelan Navy Hospital Surabaya, Fatmawati Hospital Jakarta, Hasan Sadikin Hospital Bandung and Sidoarjo Regional General Hospital, East Java.


– .

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.